Status:
COMPLETED
Genomic Testing and Resulting Medical Decisions
Lead Sponsor:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Collaborating Sponsors:
Roche Pharma AG
AstraZeneca
Conditions:
Cancer of Unknown Origin
Cancer Refractory
Eligibility:
All Genders
18+ years
Brief Summary
There is no evidence available about which molecular profiling methods are currently used for cancer patients in Austrian clinical practice. The construction of the registry proposed as a completely i...
Detailed Description
In the situation of enormous possible beneficial options for patients, health care systems, researchers and companies and the simultaneously present high number of uncertainties, the establishment of ...
Eligibility Criteria
Inclusion
- This registry will include cancer patients for which broad genomic profiling is indicated as assessed by the medical need and as deemed appropriate by the physician, for example
- cancer with high mutational load and suspicion of regular or frequent formation of neoantigens
- skin, lung, stomach, esophagus, colorectum, bladder, uterus, cervix, liver, head and neck, kidney, breast
- lymphoma B-cell
- any other neoplastic disease where molecular targeting is performed but treatment fails
- cancer of unknown primary origin (CUP)
- planned or already carried out comprehensive genomic testing as of Jan 1, 2016 note: this registry will not initially register patients who are tested for only 1-5 mutations by conventional means, but patients undergoing genomic profiling based on NGS)
- a patient´s signed informed consent
- Patients ≥ 18 years of age
Exclusion
- Due to the non-interventional design of the registry there are no specific exclusion criteria.
Key Trial Info
Start Date :
March 30 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2024
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT03301493
Start Date
March 30 2017
End Date
November 30 2024
Last Update
April 10 2025
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
IIIrd Medical Department, Private Medical University Hospital Salzburg
Salzburg, Salzburg, Austria, 5020
2
Innere Medizin II, LKH Feldkirch
Feldkirch, Austria, 6807
3
Medizinische Universitaet Graz, Univ.-Klinik f. Innere Medizin, Onkologie
Graz, Austria, A-8036
4
Medizinische Universität Innsbruck
Innsbruck, Austria, 6020